Hundreds of thousands of Australians live with severe asthma and chronic rhinosinusitis, two conditions that can cause severe daily symptoms. To help address this issue, Australia's Therapeutic Goods Administration (TGA) has approved a new treatment as an add-on maintenance therapy for people with these conditions.
Note: The information shared in this interview is of general nature and may not suit your personal situation. Please consult your healthcare provider for advice specific to your circumstances.
Approximately 200,000 Australians are currently living with the health challenge of severe asthma and chronic rhinosinusitis.
These debilitating conditions cause severe daily symptoms and trigger tens of thousands of emergency department visits, significantly impacting patients' quality of life and placing a burden on the healthcare system.
To address this challenge, Australia’s Therapeutic Goods Administration (TGA) has approved GSK Australia’s Exdensur (depemokimab) as an add-on maintenance therapy.
This innovative treatment represents a significant breakthrough as it requires administration only twice a year, helping to control symptoms in the long term, reducing the burden of daily routines, and offering new hope to patients with severe asthma and nasal polyps.
In this podcast, Professor Jo Douglass — a medical specialist and Professor of Medicine at the University of Melbourne — explains what severe asthma and nasal polyps are, their impact on patients' daily lives, and the new treatment breakthroughs approved by the TGA.
If you or your loved one are struggling with severe asthma or persistent sinus symptoms, consult a general practitioner or respiratory specialist to discuss whether the new option is right for you.
Listen to the full podcast.
